References
- Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, Witte MT, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419–25.
- Fleming RE, Bacon BR. Orchestration of iron homeostasis. N Engl J Med 2005;352:1741–4.
- Papanikolaou G, Tzilianos M, Christakis JI, Bogdanos D, Tsimirika K, MacFarlane J, Goldberg YP, Sakellaropoulos N, Ganz T, Nemeth E. Hepcidin in iron overload disorders. Blood 2005;105:4103–5.
- Gagliardo B, Kubat N, Faye A, Jaouen M, Durel B, Deschemin JC, Canonne-Hergaux F, Sari MA, Vaulont S. Pro-hepcidin is unable to degrade the iron exporter ferroportin unless maturated by a furin-dependent process. J Hepatol 2009;50:394–401.
- Kulaksiz H, Gehrke SG, Janetzko A, Rost D, Bruckner T, Kallinowski B, Stremmel W. Pro-hepcidin: expression and cell specific localization in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anaemia. Gut 2004;53:735–43.
- Koca SS, Isik A, Ustundag B, Metin K, Aksoy K. Serum pro-hepcidin levels in rheumatoid arthritis and systemic lupus erythematosus. Inflammation 2008;31:146–53.
- Gagliardo B, Faye A, Jaouen M, Deschemin JC, Canonne-Hergaux F, Vaulont S, Sari MA. Production of biologically active forms of recombinant hepcidin, the iron-regulatory hormone. FEBS J 2008;275:3793–803.
- Barisani D, Pelucchi S, Mariani R, Galimberti S, Trombini P, Fumagalli D, Meneveri R, Nemeth E, Ganz T, Piperno A. Hepcidin and iron-related gene expression in subjects with dysmetabolic hepatic iron overload. J Hepatol 2008;49:123–33.
- Fleming MD. The regulation of hepcidin and its effects on systemic and cellular iron metabolism. Hematology 2008; 151–8.
- Nemeth E. Iron regulation and erythropoiesis. Curr Opin Hematol 2008;15:169–75.
- Tsuchihashi D, Abe T, Komaba H, Fujii H, Hamada Y, Nii-Kono T, Tanaka M, Fukagawa M. Serum pro-hepcidin as an indicator of iron status in dialysis patients. Therapeut Apheresis Dialysis 2008;12:226–31.
- Kemna EH, Kartikasari AE, van Tits LJ, Pickkers P, Tjalsma H, Swinkels DW. Regulation of hepcidin: Insights from biochemical analyses on human serum samples. Blood Cells Mol Diseases 2008;40:339–46.
- Hsu SP, Chiang CK, Chien CT, Hung KY. Plasma prohepcidin positively correlates with hematocrit in chronic hemodialysis patients. Blood Purificat 2006;24:311–6.
- Chełchowska M, Swiatek E, Ambroszkiewicz J, Gajewska J, Laskowska-Klita T, Leibschang J. Concentrations of pro-hepcidin in serum of pregnant women and in umbilical cord blood. Ginekol Pol 2008;79:754–7.
- Winder A, Lefkowitz R, Ghoti H, Leiba M, Ganz T, Nemeth E, Rachmilewitz EA. Urinary hepcidin excretion in patients with myelodysplastic syndrome and myelofibrosis. Br J Haematol 2008;142:669–71.
- Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, Moroney JW, Reed CH, Luban NL, Wang RH, Eling TE, Childs R, Ganz T, Leitman SF, Fucharoen S, Miller JL. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nature Med 2007;13: 1096–101.
- Murphy PT, Mitra S, Gleeson M, Desmond R, Swinkels DW. Urinary hepcidin excretion in patients with low grade myelodysplastic syndrome. Br J Haematol 2009; 144:451–2.
- Mariani R, Pelucchi S, Pozzi M, Paolini V, Piperno A. Reduced expression of hepcidin in patients with myelodysplastic syndrome and myelofibrosis: the causes might be more heterogeneous than in thalassaemia. Br J Haematol 2008;143: 746–7.
- Piperno A, Mariani R, Trombini P. Hepcidin modulation in human diseases: from research to clinic. World J Gastroenterol 2009;15:538–51.